Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
There are a variety of hepatitis C treatments offered for all genotypes, with various stages of liver damage.
The presence of less studied HCV genotypes may compromise cure rates.
An experimental hepatitis C virus (HCV) treatment regimen given for just six or eight weeks has shown promise in a mid-stage trial.
The FDA has approved Merck’s once-daily, fixed-dose combination tablet Zepatier to treat people with genotypes 1 and 4 of hep C.
Eight or 12 weeks of AbbVie’s investigational hepatitis C treatments ABT-493 and ABT-530 cured 97 to 100 percent of people with genotype 1.
With about half of people with genotype 1 able to take just eight weeks of Harvoni, the race is on to best this treatment length or offer it t...
Studies of Gilead Sciences’ Harvoni and AbbVie’s Viekira Pak have boasted excellent cure rates among people with genotype 1 of hep C and cirrh...
Gilead Sciencesâ€™ Harvoni (ledipasvir/sofosbuvir), with or without ribavirin, cures 92 to 100 percent of people with genotype 1 of hepat...
Daclatasvir and Sovaldi, with or without ribavirin, cures high rates of people with genotype 1 of hepatitis C, according to preliminary data i...
Eight weeks of Merck’s grazoprevir/elbasvir, plus Gilead Science’ Sovaldi cured high rates of people with genotype 1 or 3 of hepatitis C.
This article which originally appeared in the HCV Advocate, discusses the the global spread of hepatitis C genotype 1
Groundbreaking new hep C treatments have been approved for people with genotype 1 of the virus. Insurers are striking coverage deals with the...
Twelve weeks of AbbVie’s ’3D’ regimen cured 93.5 percent of those with genotype 1 of hep C who were coinfected with HIV, including those with...
Eight weeks of Sovaldi and GS-5816, with or without ribavirin, cured high rates of people with genotype 3 of hepatitis C, but yielded unsatisf...
Twelve weeks of BMS’s TRIO combo pill cured 91 percent of people with genotype 1 of hepatitis C who didn’t have cirrhosis in a recent trial.
Twelve weeks of BMS’s ?TRIO? combo pill, with ribavirin, cured 93 to 98 percent of people with genotype 1 of hep C who had cirrhosis in a rece...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.